Abstract
The equivalence of the US Orange Book in China, the "CN
Orange Book" has been operating since 29 June 2021. This
"CN Orange Book" is a mountain full of treasures, for
example clear indication on what claim is covering which subject
matter in a particular drug patent. This "unofficial"
user guide aims to provide foreigners information on how to
navigate this "CN Orange Book", which operates in
Chinese.
* * * * * * * * * *
In the US, the Orange Book is a publication from the US FDA that
identifies drug products with marketing approval from the FDA and
related patent and exclusivity information. Information in the
Orange Book could be used in actions under the Hatch-Waxman Act,
which allows a patentee to file an artificial act of infringement
that allows the drug innovator to file suit before the generic drug
is commercialized, such that the drug marketing approval process of
the generic drug at the US FDA could be suspended.